# Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

> **NCT05116826** · PHASE1 · COMPLETED · sponsor: **Genfit** · enrollment: 25 (actual)

## Conditions studied

- Moderate Hepatic Impairment
- Severe Hepatic Impairment
- Liver Diseases

## Interventions

- **DRUG:** Nitazoxanide

## Key facts

- **NCT ID:** NCT05116826
- **Lead sponsor:** Genfit
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-05
- **Primary completion:** 2022-04-08
- **Final completion:** 2022-04-13
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116826, "Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05116826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*